Valneva reports latest findings from chikungunya vaccine trial

Valneva reports latest findings from chikungunya vaccine trial

Source: 
Clinical Trials Arena
snippet: 

Valneva has reported the latest positive antibody persistence data from its Study VLA1553-303 of a single dose of chikungunya vaccine, IXCHIQ.